A Phase I/IIa Theranostic Study of 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer
Latest Information Update: 18 Apr 2025
At a glance
- Drugs 64Cu SAR bisPSMA-Clarity Pharmaceuticals (Primary) ; 67Cu SAR bisPSMA-Clarity Pharmaceuticals (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Diagnostic use; Therapeutic Use
- Acronyms SECuRE
- Sponsors Clarity Pharmaceuticals
Most Recent Events
- 15 Apr 2025 Results presented in the Clarity Pharmaceuticals Media Release.
- 15 Apr 2025 According to a Clarity Pharmaceuticals media release, the first participant has been treated with the first dose of 8 GBq of 67Cu-SAR-bisPSMA in the Phase II Cohort Expansion Phase. Dosing of patient follows the recent successful completion of the Dose Escalation Phase (Phase I) of the trial and subsequent SRC recommendation to progress to the Cohort Expansion.
- 05 Mar 2025 Results presented in a Clarity Pharmaceuticals Media Release.